Form 4: NeuroPace Director Uri Geiger Increases Direct Shareholdings Through Compensation Plan

NeuroPace Inc. Director Uri Geiger has significantly increased his direct beneficial ownership of company common stock through a series of acquisitions as part of his non-employee director compensation policy.

Summary

• Uri Geiger, a Director of NeuroPace Inc. (NPCE), has acquired additional shares of common stock through a series of transactions.
• These acquisitions were made pursuant to the Issuer's non-employee director compensation policy, in lieu of quarterly retainer fees.
• Between June 30, 2023, and June 21, 2025, Mr. Geiger acquired a total of 12,036 shares directly.
• The acquisition prices for these shares ranged from $4.49 to $13.20 per share.
• Following these transactions, Mr. Geiger directly beneficially owns 12,036 shares of NeuroPace Common Stock.
• Additionally, Mr. Geiger indirectly beneficially owns 4,432,948 shares held by Accelmed Partners II LP, over which he has sole voting and dispositive power as the managing partner of Accelmed LLC.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the acquisitions are part of a compensation plan rather than discretionary purchases, the consistent increase in direct beneficial ownership by a director, coupled with significant indirect holdings, indicates continued alignment of interests and confidence in the company's long-term prospects.

Positives

• The director's direct beneficial ownership of NeuroPace common stock has increased to 12,036 shares, indicating continued alignment with shareholder interests.
• The acquisition of shares as compensation demonstrates the company's commitment to equity-based remuneration for its non-employee directors.

Future Outlook

NA

Industry Context

This filing reflects a standard compensation practice for non-employee directors, where equity is granted in lieu of cash fees. While not indicative of discretionary open-market purchases, it aligns the director's financial interests with the long-term performance of NeuroPace, a company operating in the medical device or neurotechnology sector.

Related Party Transactions

• Uri Geiger indirectly beneficially owns 4,432,948 shares held by Accelmed Partners II LP. Mr. Geiger is the managing partner of Accelmed LLC, which is the general partner of Accelmed Partners II GP, L.P., which in turn is the general partner of Accelmed Partners II LP. This structure gives him sole voting and dispositive power over these shares, representing a significant related-party holding.

Stakeholder Impact

• Shareholders: The increase in director's direct shareholding, even as compensation, aligns the director's interests with shareholders, potentially signaling confidence in the company's future performance.
• Management: The equity-based compensation policy helps attract and retain qualified non-employee directors by offering a stake in the company's success.

Key Dates

Recommendation

Keywords

NeuroPace, NPCE, SEC Form 4, Insider Trading, Director Compensation, Stock Acquisition, Beneficial Ownership, Uri Geiger, Accelmed Partners